These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 19227562)
1. Study may point way forward for bevirimat. Proj Inf Perspect; 2008 Dec; (47):11. PubMed ID: 19227562 [No Abstract] [Full Text] [Related]
2. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699 [TBL] [Abstract][Full Text] [Related]
3. Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response. Sax PE AIDS Clin Care; 2008 Dec; 20(12):104. PubMed ID: 19274775 [No Abstract] [Full Text] [Related]
4. Maturation inhibitors as new antiretroviral agents. Richards J; McCallister S J HIV Ther; 2008 Dec; 13(4):79-82. PubMed ID: 19418657 [No Abstract] [Full Text] [Related]
5. Can the further clinical development of bevirimat be justified? Wainberg MA; Albert J AIDS; 2010 Mar; 24(5):773-4. PubMed ID: 20154583 [No Abstract] [Full Text] [Related]
6. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. Seclén E; González Mdel M; Corral A; de Mendoza C; Soriano V; Poveda E AIDS; 2010 Jan; 24(3):467-9. PubMed ID: 19996935 [TBL] [Abstract][Full Text] [Related]
7. Molecule of the month. PA-457. Drug News Perspect; 2004 May; 17(4):283. PubMed ID: 15334176 [No Abstract] [Full Text] [Related]
8. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor. Temesgen Z; Feinberg JE Curr Opin Investig Drugs; 2006 Aug; 7(8):759-65. PubMed ID: 16955688 [TBL] [Abstract][Full Text] [Related]
9. The absorption, distribution, metabolism and elimination of bevirimat in rats. Bullock P; Larsen D; Press R; Wehrman T; Martin DE Biopharm Drug Dispos; 2008 Oct; 29(7):396-405. PubMed ID: 18615840 [TBL] [Abstract][Full Text] [Related]
10. Maturation inhibitors: a new therapeutic class targets the virus structure. Salzwedel K; Martin DE; Sakalian M AIDS Rev; 2007; 9(3):162-72. PubMed ID: 17982941 [TBL] [Abstract][Full Text] [Related]
11. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants. Yebra G; Holguín A Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334 [TBL] [Abstract][Full Text] [Related]
12. PA-457, new kind of antiretroviral: ten-day clinical trial results. James JS AIDS Treat News; 2005 Aug; (414):7-8. PubMed ID: 16206398 [TBL] [Abstract][Full Text] [Related]
13. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia]. Kazennova EV; Vasil'ev AV; Bobkova MR Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080 [TBL] [Abstract][Full Text] [Related]
14. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat. Connor A; Evans P; Doto J; Ellis C; Martin DE J Clin Pharmacol; 2009 May; 49(5):606-12. PubMed ID: 19304891 [TBL] [Abstract][Full Text] [Related]
15. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Martin DE; Salzwedel K; Allaway GP Antivir Chem Chemother; 2008; 19(3):107-13. PubMed ID: 19024627 [TBL] [Abstract][Full Text] [Related]